MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 530018 | Name: Fluasterone
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fluasterone, also known as HE2500, is an NF-κB activation inhibitor potentially for the treatment of metabolic syndrome.

Chemical Structure

Fluasterone
Fluasterone
CAS#112859-71-9

Theoretical Analysis

MedKoo Cat#: 530018

Name: Fluasterone

CAS#: 112859-71-9

Chemical Formula: C19H27FO

Exact Mass: 290.2000

Molecular Weight: 290.42

Elemental Analysis: C, 78.58; H, 9.37; F, 6.54; O, 5.51

Price and Availability

Size Price Availability Quantity
5mg USD 550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
HE-2500; HE2500; HE 2500; Fluasterone
IUPAC/Chemical Name
(8R,9S,10R,13S,14S,16R)-16-fluoro-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
InChi Key
VHZXNQKVFDBFIK-NBBHSKLNSA-N
InChi Code
InChI=1S/C19H27FO/c1-18-9-4-3-5-12(18)6-7-13-14(18)8-10-19(2)15(13)11-16(20)17(19)21/h6,13-16H,3-5,7-11H2,1-2H3/t13-,14+,15+,16-,18+,19+/m1/s1
SMILES Code
O=C1[C@H](F)C[C@@]2([H])[C@]3([H])CC=C4CCCC[C@]4(C)[C@@]3([H])CC[C@]12C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 290.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Burgess JP, Green JS, Hill JM, Zhan Q, Lindeblad M, Lyubimov A, Kapetanovic IM, Schwartz A, Thomas BF. Identification of [14C]fluasterone metabolites in urine and feces collected from dogs after subcutaneous and oral administration of [14C]fluasterone. Drug Metab Dispos. 2009 May;37(5):1089-97. doi: 10.1124/dmd.108.023614. PubMed PMID: 19196848; PubMed Central PMCID: PMC2683393. 2: Lindeblad MO, Bauer KS, Zakharov AD, Hill JM, Green JS, Thomas BF, Schwartz A, Kapetanovic IM, Lyubimov A. Pharmacokinetic and tissue distribution study of [14C]fluasterone in male Beagle dogs following intravenous, oral and subcutaneous dosing routes. Chem Biol Interact. 2010 Jan 27;183(2):317-26. doi: 10.1016/j.cbi.2009.10.004. PubMed PMID: 19836365. 3: McCormick DL, Johnson WD, Kozub NM, Rao KV, Lubet RA, Steele VE, Bosland MC. Chemoprevention of rat prostate carcinogenesis by dietary 16alpha-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone. Carcinogenesis. 2007 Feb;28(2):398-403. PubMed PMID: 16952912. 4: He Y, Li P, Yalkowsky SH. Solubilization of Fluasterone in cosolvent/cyclodextrin combinations. Int J Pharm. 2003 Oct 2;264(1-2):25-34. PubMed PMID: 12972333. 5: Zhao L, Li P, Yalkowsky SH. Solubilization of fluasterone. J Pharm Sci. 1999 Oct;88(10):967-9. PubMed PMID: 10514340. 6: Ciolino HP, MacDonald CJ, Yeh GC. Inhibition of carcinogen-activating enzymes by 16alpha-fluoro-5-androsten-17-one. Cancer Res. 2002 Jul 1;62(13):3685-90. PubMed PMID: 12097275. 7: Offner H, Zamora A, Subramanian S, Polanczyk M, Krogstad A, Auci DL, Morgan EE, Reading CL. A synthetic androstene analogue inhibits collagen-induced arthritis in the mouse. Clin Immunol. 2004 Feb;110(2):181-90. PubMed PMID: 15003815. 8: Malik AS, Narayan RK, Wendling WW, Cole RW, Pashko LL, Schwartz AG, Strauss KI. A novel dehydroepiandrosterone analog improves functional recovery in a rat traumatic brain injury model. J Neurotrauma. 2003 May;20(5):463-76. PubMed PMID: 12803978; PubMed Central PMCID: PMC1456324. 9: Schwartz AG, Pashko LL. Inhibition of adjuvant-induced arthritis by 16 alpha-fluoro-5-androsten-17-one. Mil Med. 2002 Feb;167(2 Suppl):60-3. PubMed PMID: 11873519. 10: Offner H, Zamora A, Drought H, Matejuk A, Auci DL, Morgan EE, Vandenbark AA, Reading CL. A synthetic androstene derivative and a natural androstene metabolite inhibit relapsing-remitting EAE. J Neuroimmunol. 2002 Sep;130(1-2):128-39. PubMed PMID: 12225895. 11: Li P, Zhao L, Yalkowsky SH. Combined effect of cosolvent and cyclodextrin on solubilization of nonpolar drugs. J Pharm Sci. 1999 Nov;88(11):1107-11. PubMed PMID: 10564056. 12: Shilkaitis A, Green A, Punj V, Steele V, Lubet R, Christov K. Dehydroepiandrosterone inhibits the progression phase of mammary carcinogenesis by inducing cellular senescence via a p16-dependent but p53-independent mechanism. Breast Cancer Res. 2005;7(6):R1132-40. PubMed PMID: 16457693; PubMed Central PMCID: PMC1410767. 13: Christov KT, Moon RC, Lantvit DD, Boone CW, Kelloff GJ, Steele VE, Lubet RA, Pezzuto JM. Prostate intraepithelial neoplasia in Noble rats, a potential intermediate endpoint for chemoprevention studies. Eur J Cancer. 2004 Jun;40(9):1404-11. PubMed PMID: 15177500. 14: Schwartz AG, Pashko LL. Suppression of 12-O-tetradecanoylphorbol-13-acetate-induced epidermal hyperplasia and inflammation by the dehydroepiandrosterone analog 16alpha-fluoro-5-androsten-17-one and its reversal by NADPH liposomes. Cancer Lett. 2001 Jul 10;168(1):7-14. PubMed PMID: 11368871. 15: Offner H. Neuroimmunoprotective effects of estrogen and derivatives in experimental autoimmune encephalomyelitis: therapeutic implications for multiple sclerosis. J Neurosci Res. 2004 Dec 1;78(5):603-24. Review. PubMed PMID: 15515048. 16: Holzman D. Green tea, mistletoe, and more: Canadians test alternative cancer therapies. J Natl Cancer Inst. 1997 May 21;89(10):683-4. PubMed PMID: 9168180. 17: McNeil C. Potential drug DHEA hits snags on way to clinic. J Natl Cancer Inst. 1997 May 21;89(10):681-3. PubMed PMID: 9168179. 18: Burgess JP, Wintermute JS, Thomas BF, Kapetanovic IM. Complete 1H and 13C assignments of fluorinated analogs of dehydroepiandrosterone. Magn Reson Chem. 2006 Nov;44(11):1051-3. PubMed PMID: 16835888. 19: Ware JH, Zhou Z, Kopelovich L, Kennedy AR. Evaluation of cancer chemopreventive agents using clones derived from a human prostate cancer cell line. Anticancer Res. 2006 Nov-Dec;26(6B):4177-83. PubMed PMID: 17201130. 20: Whitnall MH, Villa V, Seed TM, Benjack J, Miner V, Lewbart ML, Dowding CA, Jackson WE 3rd. Molecular specificity of 5-androstenediol as a systemic radioprotectant in mice. Immunopharmacol Immunotoxicol. 2005;27(1):15-32. PubMed PMID: 15803857.